That starts to get into the realm of being unambiguously unfair. At the very least, they probably should've paid more money for it so that the people who developed the drug could've gotten their share.
Maybe it was just a risky purchase that turned out unexpectedly successful. I've never evaluated a $10+ billion deal, but I imagine I'd be scared of it falling through if I asked for too much.
That starts to get into the realm of being unambiguously unfair. At the very least, they probably should've paid more money for it so that the people who developed the drug could've gotten their share.
Maybe it was just a risky purchase that turned out unexpectedly successful. I've never evaluated a $10+ billion deal, but I imagine I'd be scared of it falling through if I asked for too much.